China-based IASO Biotechnology announced the completion of its acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering and cell therapy company.
The deal will integrate MediSix's differentiated T-cell engineering platform, R&D pipeline, and international talent team with IASO Bio’s cell therapy, manufacturing and commercialization capabilities, enabling IASO Bio to further globalize.
MediSix's core technology focuses on addressing key challenges in cell therapy for T-cell malignancies. Its proprietary PEBL (Protein Expression Blocker) platform can specifically block the expression of target proteins on cell surfaces, effectively reducing fratricide among CAR-T cells. This enables targeting of antigens shared between T-cells and target cells, and by combining ex vivo and in vivo CAR-T approaches, has established exclusive technological barriers and advantages for treating hematologic malignancies, solid tumors, and other diseases.
MediSix’s lead program, PCART7, is an autologous anti-CD7 CAR-T cell therapy developed to treat T-cell malignancies like T-cell acute lymphoblastic leukemia and lymphoma. The therapy is currently undergoing clinical evaluation.
The financial terms of the deal were not disclosed.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!